Welcome to our dedicated page for Aktis Oncology SEC filings (Ticker: AKTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aktis Oncology, Inc. filings document the company’s transition into a Nasdaq-listed public oncology issuer and its disclosure obligations as a clinical-stage oncology company. S-1/A registration materials and current reports describe its targeted radiopharmaceutical pipeline, including AKY-1189 and AKY-2519, the miniprotein radioconjugate platform, collaboration revenue, and operating results.
Its filings also cover post-IPO governance and capital-structure matters, including amended charter provisions, authorized common, Class A common and undesignated preferred stock, classified board provisions, director appointments, board committee structure, financial-results exhibits, and registered common stock under the AKTS symbol.
Aktis Oncology director Ken Herrmann exercised vested stock options and sold the resulting shares on July 20, 2026. He exercised options for 3,506 shares at $0.08 per share and 1,350 shares at $1.91 per share, acquiring 4,856 common shares. He then sold 4,856 common shares at a weighted average price of $24.5622 per share in transactions priced between $24.50 and $24.66.
Aktis Oncology, Inc. director Ken Herrmann reported a same-day option exercise and sale. He exercised 3,065 stock options at $0.0800 per share into 3,065 shares of common stock, then sold 3,065 shares at a weighted average price of $25.2067, with individual trades between $25.00 and $25.4950. The exercised options were fully vested, and 3,506 options from this award remained outstanding, expiring November 23, 2030.
Akoustis Technologies, Inc. (AKTS) has a notice of proposed sale of common stock by an affiliate. A brokerage account at Morgan Stanley Smith Barney LLC Executive Financial Services is listed for the planned sale of 4,856 shares of common stock on July 20, 2026 on NASDAQ.
The shares are indicated as coming from a stock option exercise, with a stated market value of $119,274.53. The filing also notes that on July 17, 2026, Ken Herrmann sold 3,065 shares of common stock over the prior three months for $77,258.54 in aggregate.
Aktis Oncology, Inc. executive Shulamit Ron-Bigger, Chief Operating Officer, reported an exercise-and-sale transaction in company equity. On July 8, 2026, she exercised stock options to acquire 50,000 shares of common stock at an exercise price of $3.66 per share and on the same date sold 50,000 shares of common stock in multiple open-market transactions at weighted average prices around the high-$20s per share. After these transactions, she continued to hold 217,888 stock options expiring in 2032.
Aktis Oncology, Inc. Chief Medical Officer Akos Czibere reported an exercise-and-sell transaction in Common Stock on July 8, 2026. He exercised stock options to acquire 50,000 shares at $4.95 per share, then sold 50,000 shares in multiple open-market sales at weighted average prices around the high-$20s range, leaving no Common Stock held directly and 221,218 stock options outstanding with a $4.95 exercise price expiring on June 30, 2034.
Aktis Oncology, Inc. Schedule 13G shows Blue Owl Capital Holdings LP reports beneficial ownership of 3,161,348 shares of common stock, representing 5.92% of the class. The percentage is calculated from March 10, 2026 outstanding shares of 53,403,173, as disclosed in the issuer's 10-K.
Aktis Oncology reported its first quarterly results as a public company, showing higher collaboration revenue and a much stronger balance sheet after its IPO. Collaboration revenue from its Eli Lilly partnership grew to $3.2 million for the three months ended March 31, 2026, up from $1.4 million a year earlier. Operating expenses rose to $25.9 million, driven mainly by increased R&D spending on lead radiopharmaceutical candidates [225Ac]Ac-AKY-1189 and [225Ac]Ac-AKY-2519 and higher public-company G&A costs, resulting in a net loss of $18.3 million versus $15.0 million in 2025. The January 2026 IPO and preferred share conversion transformed the capital structure, leaving Aktis with $538.5 million in cash, cash equivalents and marketable securities and total stockholders’ equity of $506.1 million. Management believes this cash runway will fund operations into 2029 as the company advances its miniprotein radioconjugate platform and clinical programs.